Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracic radiotherapy plus anlotinib in stage III–IV lung squamous cell carcinoma intolerant of chemotherapy
ChiCTR2200062888Phase 2Recruiting
- Sponsor
- Shaoxing People's Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Pulmonary squamous cell carcinoma, sponsored by Shaoxing People's Hospital. Primary endpoint: Progression-free survival time. Started Aug 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2200062888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062888.